Kyverna Therapeutics, Inc. KYTX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Kyverna Therapeutics, Inc. (KYTX) reported unrealized gains (losses) on available-for-sale securities of -$193K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Kyverna Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 82.1% year-over-year, from -$106K to -$193K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric represents the change in the fair value of investment securities classified as available-for-sale that has not yet been realized through a sale. It captures fluctuations in the market value of the company's investment portfolio that are recognized in equity rather than the income statement. Monitoring this helps investors understand the volatility and unrealized performance of the company's treasury or investment holdings.